J. Newman

发表

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques

T. Grossman, J. Sutcliffe, Lisa N. Henning, 2017, Antimicrobial Agents and Chemotherapy.

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

D. Ehmann, S. McLeod, Camilo Velez-Vega, 2017, Nature Microbiology.

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017

I. Morrissey, M. Bassetti, J. Karlowsky, 2019, Antimicrobial Agents and Chemotherapy.

Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.

T. Dougherty, Liang Zhao, C. Eyermann, 2014, Bioorganic & medicinal chemistry.

Abstract 3880: In vivo activities of TP-2846: a novel tetracycline antileukemia agent

A. Chakravarty, B. Hibner, Xiao-yi Xiao, 2019 .

Enteropathogenic Escherichia coli and ulcerative colitis in cotton-top tamarins (Saguinus oedipus).

K. Mansfield, A. Lackner, D. Schauer, 2001, The Journal of infectious diseases.

Citrobacter rodentium, the Causative Agent of Transmissible Murine Colonic Hyperplasia, Exhibits Clonality: Synonymy of C. rodentium and Mouse-PathogenicEscherichia coli

A. Steigerwalt, M. Schrenzel, D. J. Brenner, 2000, Journal of Clinical Microbiology.

Stimulation of Escherichia coli F-18Col- type-1 fimbriae synthesis by leuX.

C. S. Kristensen, K. Krogfelt, D. Laux, 1994, FEMS microbiology letters.

Utilization of the mouse large intestine to select an Escherichia coli F-18 DNA sequence that enhances colonizing ability and stimulates synthesis of type 1 fimbriae

K. Krogfelt, D. Laux, P. Cohen, 1993, Infection and immunity.

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.

D. Ehmann, M. Cronin, A. A. Godfrey, 2012, Journal of medicinal chemistry.

Formulation in Liposomes Type IIa Topoisomerase Inhibitor by Antibacterial Efficacy of a Novel In Vivoof the Pharmacokinetics and

A. Shapiro, J. Newman, Nikunj Agrawal, 2014 .

Improvement of the Pharmacokinetics and In Vivo Antibacterial Efficacy of a Novel Type IIa Topoisomerase Inhibitor by Formulation in Liposomes

A. Shapiro, J. Newman, Nikunj Agrawal, 2013, Antimicrobial Agents and Chemotherapy.

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

M. Gowravaram, G. Basarab, V. Galullo, 2015, Scientific reports.

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

M. Gowravaram, G. Basarab, V. Galullo, 2015, Scientific Reports.

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.

C. Eyermann, D. Ehmann, M. Cronin, 2011, Journal of medicinal chemistry.

Secreted Gaussia princeps Luciferase as a Reporter of Escherichia coli Replication in a Mouse Tissue Cage Model of Infection

S. McLeod, S. Fisher, Mingyu Liu, 2014, PloS one.

Pyridodiazepine Amines Are Selective Therapeutic Agents for Helicobacter pylori by Suppressing Growth through Inhibition of Glutamate Racemase but Are Predicted To Require Continuous Elevated Levels in Plasma To Achieve Clinical Efficacy

Wei Yang, B. D. de Jonge, J. Newman, 2015, Antimicrobial Agents and Chemotherapy.

NBTI 5463 Is a Novel Bacterial Type II Topoisomerase Inhibitor with Activity against Gram-Negative Bacteria and In Vivo Efficacy

T. Dougherty, D. Ehmann, M. Cronin, 2014, Antimicrobial Agents and Chemotherapy.

NBTI 5463 Is a Novel Bacterial Type II Topoisomerase Inhibitor with Activity against Gram-Negative Bacteria and In Vivo Efficacy

T. Dougherty, D. Ehmann, M. Cronin, 2014, Antimicrobial Agents and Chemotherapy.

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

M. Gowravaram, G. Basarab, V. Galullo, 2015, Scientific Reports.

Novel Bacterial NAD+-Dependent DNA Ligase Inhibitors with Broad-Spectrum Activity and Antibacterial Efficacy In Vivo

Kenneth D. Johnson, Wei Yang, A. Eakin, 2010, Antimicrobial Agents and Chemotherapy.

Role of leuX in Escherichia coli colonization of the streptomycin-treated mouse large intestine.

R. Kolter, D. Laux, P. Cohen, 1994, Microbial pathogenesis.

Discovery of bacterial NAD⁺-dependent DNA ligase inhibitors: improvements in clearance of adenosine series.

M. Gowravaram, T. O'Shea, S. D. Mills, 2012, Bioorganic & medicinal chemistry letters.

Novel Bacterial NAD +-dependent DNA Ligase Inhibitors with 3 Broad Spectrum Activity and Antibacterial Efficacy In Vivo 4 5 6 Running title : Novel Bacterial NAD +-dependent DNA Ligase Inhibitors 7 8 9

Kenneth D. Johnson, Wei Yang, A. Eakin, 2010 .

Bacterial infection promotes colon tumorigenesis in Apc(Min/+) mice.

T. Kosaka, J. Fox, B. Sheppard, 2001, The Journal of infectious diseases.

In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound.

Diane Joseph-McCarthy, Sameer Kawatkar, D. Joseph-McCarthy, 2012, ACS chemical biology.

Antibacterial inhibitors of Gram-positive thymidylate kinase: structure-activity relationships and chiral preference of a new hydrophobic binding region.

T. Keating, Gabriel Martínez-Botella, John N Breen, 2014, Journal of medicinal chemistry.

Discovery of selective and potent inhibitors of gram-positive bacterial thymidylate kinase (TMK).

Diane Joseph-McCarthy, Jon Read, Sameer Kawatkar, 2012, Journal of medicinal chemistry.

Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects

Jian Zhou, L. Tsai, J. Newman, 2018, Antimicrobial Agents and Chemotherapy.

1963. Combined Microbiological Response Rates From Two Phase 3 Trials Demonstrating the Activity of Eravacycline in the Treatment of Complicated Intra-abdominal Infections: A Pooled Analysis of IGNITE1 and IGNITE4

C. Fyfe, L. Tsai, J. Newman, 2018, Open Forum Infectious Diseases.

Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits

A. Mutlib, T. Walsh, R. S. Singh, 2018, Antimicrobial Agents and Chemotherapy.

Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline

Jian Zhou, L. Tsai, J. Newman, 2018, Antimicrobial Agents and Chemotherapy.

Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis.

D. Nicolau, M. Monogue, A. Thabit, 2018, International journal of antimicrobial agents.

Efficacy In Vivo against Gram-Negative Bacteria and Topoisomerase Inhibitor with Activity NBTI 5463 Is a Novel Bacterial Type II

T. Dougherty, M. Cronin, F. Reck, 2014 .

NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with Gram-6 negative antibacterial activity and in vivo efficacy

T. Dougherty, D. Ehmann, M. Cronin, 2014 .